Clinical trial / 2005
Daily vitamin E supplementation did not reduce the risk of progression from mild cognitive impairment to Alzheimer's disease over three years.
In a double-blind trial, 769 subjects with amnestic mild cognitive impairment were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. Over three years, possible or probable Alzheimer's disease developed in 212 subjects. Compared to placebo, there were no significant differences in progression to Alzheimer's disease in the vitamin E group (hazard ratio, 1.02; 95% CI, 0.74 to 1.41; P=0.91) or the donepezil group (hazard ratio, 0.80; 95% CI, 0.57 to 1.13; P=0.42). Donepezil reduced progression likelihood during the first 12 months (P=0.04), but vitamin E showed no benefit at any point, including among apolipoprotein E epsilon4 carriers.
- Study type
- Double-blind randomized controlled trial
- Who was studied
- 769 subjects with the amnestic subtype of mild cognitive impairment
- What was measured
- Progression to clinically possible or probable Alzheimer's disease; secondary outcomes were cognition and function
THE PAPER
Vitamin E and donepezil for the treatment of mild cognitive impairment.
Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer's Disease Cooperative Study Group. N Engl J Med, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.